Clinical Trial Endpoints in Oncology - Inclusion of Surrogate Endpoints and Shorter Endpoints Will Ensure Faster Clinical Trials in Oncology - GBI Research Reports

Clinical Trial Endpoints in Oncology - Inclusion of Surrogate Endpoints and Shorter Endpoints Will Ensure Faster Clinical Trials in Oncology

Clinical Trial Endpoints in Oncology - Inclusion of Surrogate Endpoints and Shorter Endpoints Will Ensure Faster Clinical Trials in Oncology - GBI Research Reports
Clinical Trial Endpoints in Oncology - Inclusion of Surrogate Endpoints and Shorter Endpoints Will Ensure Faster Clinical Trials in Oncology
Published Mar 25, 2011
120 pages — Published Mar 25, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research Clinical Trial Endpoints in Oncology Inclusion of Surrogate Endpoints and Shorter Endpoints will Ensure Faster Clinical Trials in Oncology, which essentially provides insights into clinical trial endpoints in oncology. The report details the endpoints and application of endpoints in oncological clinical trials. The report also analyzes the major four markets which include the colorectal cancer, prostate cancer, head and neck cancer and ovarian cancer therapeutics markets. It includes the analysis of endpoints of the major marketed products and their profiling. In addition to marketed products, the Phase III and Phase II clinical trials are also analyzed in terms of percentage cases. Analysis of prevailing and upcoming trends and their effects on the market and company profiling of major companies are included in the report.

Scope

The report details the endpoints and application of endpoints in Oncology Clinical Trials. The report covers -
- Data and analysis on the marketed products and analysis of endpoints used for the approval of the product.
- Analysis of the four major markets, which includes the colorectal cancer, prostate cancer, head and neck cancer and ovarian cancer therapeutics markets.
- Analysis of the Phase III and Phase II clinical trials in terms of percentage cases. Analysis of terminated trials is also included in this chapter. Only industry sponsored studies are included in the report.
- Trend Analysis analyzes prevailing and upcoming trends and their effects on the market.
- Company Profiling talks in detail about the companies which are strong in the market.

Reasons to buy

The report will help business development and marketing executives who are strategizing their product launches to -
- Build an effective R&D strategy by identifying the current state of endpoint achieved by the marketed products
- Identify the disease unmet needs for the four major cancers and align your pipeline product portfolio to tap the market potential.
- Improve our future market position by aligning your R&D pipeline to the areas with maximum success potential
- Improve your R&D efficiency by reducing research expenditure on unsuccessful endpoints
- Develop key strategic initiatives by understanding the key focus of leading companies with strong product pipeline.

  
Source:
Document ID
GBIHC061MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents34
  List of Tables51
  List of Figures61
Clinical Trials Endpoints In Oncology Introduction72
  Introduction71
  GBI Research Report Guidance81
Clinical Trials Endpoints In Oncology Market Overview94
  Endpoints Used for Regular Approval92
    Survival111
    Progression-free survival111
    Tumor Response, Response Duration, and Time-to-Tumor Progression121
    DFS121
Clinical Trials Endpoints in Oncology Therapeutic Analysis1381
  Colorectal Cancer131
    Major Marketed Drug Analysis132
    Profiling of Major Marketed Products151
      Avastin (bevacizumab)151
      Erbitux (cetuximab)161
      Xeloda (capecitabine)171
      Vectibix (panitumumab)181
      Eloxatin (oxaliplatin)192
      Camptosar (irinotecan)211
    Phase III Molecules Analysis221
    Most Promising Drugs Profiles231
      Aflibercept231
      Brivanib245
    Phase II Molecules Analysis296
    Terminated Trials351
      Vectibix Treatment Discontinued Due to Safety Issues, Metastatic Colorectal Cancer351
  Prostate Cancer361
    Major Marketed Drug Analysis362
    Profiling of Major Marketed Products381
      Taxotere (docetaxel)381
      Casodex (Bicalutamide)391
      Zoladex (Goserelin)401
      Provenge (sipuleucel-T)412
      Eligard (leuprolide acetate)431
      Prostap (leuprolide acetate)441
      Firmagon (degarelix)451
      Vantas (histrelin)462
      Novantrone (mitoxantrone hydrochloride)481
      Trelstar (triptorelin)491
    Phase III Molecules Analysis501
    Most Promising Drugs Profiles511
      Aflibercept (VEGF Trap)511
      Ipilimumab521
      Abiraterone Acetate (CB7630)531
      Zibotentan (ZD4054)544
    Phase II Molecules Analysis585
    Terminated Trials631
      Pfizer Discontinues Sutent Prostate Cancer Trial631
  Head and Neck Cancer Therapeutics631
    Major Marketed Drug Analysis632
    Profiling of Major Marketed Products651
      Erbitux (cetuximab)651
      Taxotere (docetaxel)661
      Oncorine (H101, Modified Adenovirus)671
      Gendicine (Recombinant Human Ad-P53)681
    Phase III Molecules Analysis681
      Tykerb/ Tyverb (Lapatinib Ditosylate)691
      Reolysin703
    Phase II molecules Analysis733
    Terminated Trials761
      Iressa (AstraZeneca) Failed to Prolong Survival and Increased Bleeding Events in the Treatment of Squamous Cell Carcinoma of the Head and Neck (SCCHN)761
      Bivatuzumab Mertansine (Boehringer Ingelheim GmbH; Immunogen, Inc) Clinical Development Discontinued761
  Ovarian Cancer771
    Major Marketed Drug Analysis771
    Profiling of Major Marketed Products781
      Altretamine (hexalen)781
      Gemcitabine (gemzar)781
      Hycamtin (topotecan hydrochloride)791
      Yondelis801
    Phase III molecules Analysis811
      Avastin (RG435, bevacizumab)821
      Opaxio831
      Abagovomab841
      Telcyta (canfosfamide HCl)851
      Karenitecin (BNP 1350)863
    Phase II Molecules Analysis894
    Terminated Trials931
      OvaRex (United Therapeutics Corporation) Fail to Meet Primary Endpoint in Advanced Ovarian Cancer931
      Pemtumomab (Antisoma, Hoffmann-La Roche, Inc.) Dsicontinued the Study in Advanced Ovarian Cancer931
Clinical Trials Endpoints In Oncology New Trends and Technologies941
  Microsatellite Instability (MSI) as a Diagnostic Tool in Colorectal Cancer941
  New Biomarker for Aggressive Prostate Cancer941
Clinical Trials Endpoints In Oncology Company Profiling9520
  F. Hoffmann La Roche951
    Business Description951
    Financial Overview951
    Major Oncology Products961
      Avastin (bevacizumab)961
      Xeloda (capecitabine)971
  Bristol-Myers Squibb981
    Business Description981
    Financial Overview981
    Major Oncology Products981
      Erbitux (cetuximab)982
  Sanofi-Aventis1001
    Business Description1001
    Financial Overview1001
    Major Oncology Products1011
      Taxotere (docetaxel)1011
      Eloxatin (oxaliplatin)1021
  Merck KGaA1031
    Business Description1031
    Financial Overview1041
    Major Oncology Products1041
      Erbitux (cetuximab)1041
  Pfizer Inc.1051
    Business Description1051
    Financial Overview1061
    Major Oncology Products1061
      Camptosar (irinotecan)1061
  AstraZeneca1071
    Business Description1071
    Financial Overview1081
    Major Oncology Products1091
      Casodex (Bicalutamide)1091
      Zoladex (Goserelin)1101
      Clinical Study Details1111
  Takeda Pharmaceuticals1111
    Business Description1111
    Financial Overview1111
    Major Oncology Products1111
      Vectibix (panitumumab)1112
  GlaxoSmithKline plc.1131
    Business Description1131
    Financial Overview1131
    Major Oncology Products1141
      Hycamtin (topotecan hydrochloride)1141
Clinical Trials Endpoints In Oncology Appendix1156
  Market Definitions1151
  Abbreviations1153
  Research Methodology1182
    Coverage1181
    Secondary Research1181
    Primary Research1191
    Expert Panel Validation1191
  Contact Us1191
  Disclaimer1201
  Sources1201

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Clinical Trial Endpoints in Oncology - Inclusion of Surrogate Endpoints and Shorter Endpoints Will Ensure Faster Clinical Trials in Oncology" Mar 25, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Clinical-Trial-Endpoints-in-Oncology-Inclusion-of-Surrogate-Endpoints-and-Shorter-Endpoints-Will-Ensure-Faster-Clinical-Trials-in-Oncology-2115-184>
  
APA:
GBI Research Reports. (2011). Clinical Trial Endpoints in Oncology - Inclusion of Surrogate Endpoints and Shorter Endpoints Will Ensure Faster Clinical Trials in Oncology Mar 25, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Clinical-Trial-Endpoints-in-Oncology-Inclusion-of-Surrogate-Endpoints-and-Shorter-Endpoints-Will-Ensure-Faster-Clinical-Trials-in-Oncology-2115-184>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.